In our study, we examine: Trends in GLP-1 prevalence, adherence data, and potential obstacles to continued use Impacts on mortality among individuals taking these drugs Implications for assessing metabolic risk and the crucial role electronic health records (EHRs) will play Key results GLP-1s may drive 0.2%0.5% annual mortality improvement, realized over a 20-year period
Instead, we offer other evidence-based alternatives that align with your health and wellness goals, such as semaglutide, tirzepatide, other peptide therapies that support metabolic health, or hormone replacement therapy (HRT)
If you are experiencing hair loss while taking weight-loss injections, you are not alone, and you should know that this type of shedding is almost always temporary
PMCID: PMC5214347
Start with medication specifics that lay the groundwork for understanding your results
More than 70% said they support employers and insurance programs setting minimum requirements, including prior authorization, thresholds for body mass index or participation in wellness programs, for coverage of GLP-1s
